Fiche publication
Date publication
septembre 2017
Journal
ACS infectious diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
Tous les auteurs :
Colpitts CC, Chung RT, Baumert TF
Lien Pubmed
Résumé
Entry inhibitors are emerging as an attractive class of therapeutics for hepatitis C virus (HCV) infection. Entry inhibitors target either virion-associated factors or cellular factors necessary for infection. By blocking entry into cells, entry inhibitors prevent both the establishment of persistent reservoirs and the emergence of resistant variants during viral replication. Furthermore, entry inhibitors protect naïve cells from virus-induced alterations. Combining entry inhibitors with direct-acting antivirals (DAAs) may therefore improve treatment outcomes, particularly in the context of organ transplantation. The role of DAAs in transplantation, while still under clinical investigation, carries the risk of recipient infection and HCV-induced disease, since DAAs act only after infection is established. Thus, entry inhibitors provide a perspective to improve patient outcomes during organ transplantation. Applying this approach for transplant of organs from HCV-positive donors to HCV-negative recipients may also contribute to alleviate the medical burden of organ shortage.
Mots clés
Antiviral Agents, pharmacology, Clinical Trials as Topic, Hepacivirus, drug effects, Hepatitis C, prevention & control, Humans, Organ Transplantation, adverse effects, Tissue Donors, Treatment Outcome, Virus Internalization, drug effects
Référence
ACS Infect Dis. 2017 09 8;3(9):620-623
